Trials / Conditions / Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic Fatty Liver Disease (NAFLD)

22 registered clinical trials studyying Nonalcoholic Fatty Liver Disease (NAFLD) — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly NCT07068191	Phenomen Pharma	N/A
Recruiting	The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health NCT07093346	University of Nottingham	N/A
Completed	A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants NCT06024408	Regeneron Pharmaceuticals	Phase 1
Recruiting	Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis NCT03572465	Centre hospitalier de l'Université de Montréal (CHUM)	—
Completed	Postprandial Lipotoxicity and Nonalcoholic Fatty Liver Disease NCT03836443	Assistance Publique - Hôpitaux de Paris	N/A
Completed	Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease NCT03459079	University of Florida	Phase 2
Completed	A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 L NCT03486899	Bristol-Myers Squibb	Phase 2
Completed	A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cir NCT03486912	Bristol-Myers Squibb	Phase 2
Unknown	Screening With FibroTouch for Advanced Liver Fibrosis in NAFLD Patients With Underlying Type 2 Diabetes NCT03525769	Nanfang Hospital, Southern Medical University	—
Completed	Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease NCT02217345	Massachusetts General Hospital	Phase 2
Completed	Anti-LPS Antibody Treatment for Pediatric NAFLD NCT03042767	Miriam Vos, MD	Phase 2
Unknown	Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients NCT04059029	Taipei Medical University Hospital	—
Completed	Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Stea NCT02781584	Gilead Sciences	Phase 2
Completed	Tesamorelin Effects on Liver Fat and Histology in HIV NCT02196831	Massachusetts General Hospital	N/A
Terminated	Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAF NCT02244944	Gregory Graf, PhD	Phase 2
Unknown	Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease NCT02213224	Nanfang Hospital, Southern Medical University	Phase 4
Completed	Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound NCT02044523	Centre hospitalier de l'Université de Montréal (CHUM)	—
Terminated	Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance Biomarkers in Nonalcoholic Fatty L NCT01930123	Manal F Abdelmalek	Phase 2
Unknown	Multimodal Approach in IBD Patients NCT01705522	Clinical Hospital Colentina	—
Completed	Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children NCT01529268	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2 / Phase 3
Unknown	Nonalcoholic Fatty Liver Disease (NAFLD) Pharmacological Treatment: Metformin Versus Atorvastatin NCT01544751	Prof Antonino Belfiore	N/A
Completed	The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT) NCT01265498	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2